Combination Product: TransCon PTH ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
235	Hypoparathyroidism	2

235. Hypoparathyroidism

---

Clinical trials : 88 /  Drugs : 128 - (DrugBank : 25) / Drug target genes : 5 - Drug target pathways : 7

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04701203 (ClinicalTrials.gov)	February 16, 2021	6/1/2021	A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism	PaTHway TRIAL: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial, With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With Hypoparathyroidism	Hypoparathyroidism;Endocrine System Diseases;Parathyroid Diseases	Combination Product: TransCon PTH;Combination Product: Placebo	Ascendis Pharma Bone Diseases A/S	NULL	Active, not recruiting	18 Years	N/A	All	82	Phase 3	United States;Canada;Denmark;Germany;Hungary;Italy;Norway
2	NCT04009291 (ClinicalTrials.gov)	August 27, 2019	20/6/2019	A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism	PaTH Forward: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With Hypoparathyroidism	Hypoparathyroidism;Endocrine System Diseases;Parathyroid Diseases	Combination Product: TransCon PTH;Combination Product: Placebo for TransCon PTH	Ascendis Pharma A/S	NULL	Active, not recruiting	18 Years	N/A	All	40	Phase 2	United States;Canada;Denmark;Germany;Italy;Norway;United Kingdom